In Vitro Susceptibility of Multidrug-Resistant Pseudomonas aeruginosa following Treatment-Emergent Resistance to Ceftolozane-Tazobactam

We compared the susceptibility of multidrug-resistant isolates collected before and after treatment-emergent resistance to ceftolozane-tazobactam. Median baseline and postexposure ceftolozane-tazobactam MICs were 2 and 64 μg/ml, respectively. Whole-genome sequencing identified treatment-emergent mut...

Full description

Saved in:
Bibliographic Details
Published in:Antimicrobial agents and chemotherapy 2021-05, Vol.65 (6)
Main Authors: Rubio, Abigail M, Kline, Ellen G, Jones, Chelsea E, Chen, Liang, Kreiswirth, Barry N, Nguyen, M Hong, Clancy, Cornelius J, Cooper, Vaughn S, Haidar, Ghady, Van Tyne, Daria, Shields, Ryan K
Format: Article
Language:English
Subjects:
Anti-Bacterial Agents - pharmacology
Cephalosporins - pharmacology
Drug Resistance, Multiple, Bacterial - genetics
Humans
Mechanisms of Resistance
Microbial Sensitivity Tests
Pseudomonas aeruginosa - genetics
Pseudomonas Infections - drug therapy
Tazobactam - pharmacology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We compared the susceptibility of multidrug-resistant isolates collected before and after treatment-emergent resistance to ceftolozane-tazobactam. Median baseline and postexposure ceftolozane-tazobactam MICs were 2 and 64 μg/ml, respectively. Whole-genome sequencing identified treatment-emergent mutations in among 79% (11/14) of paired isolates. mutations were associated with cross-resistance to ceftazidime-avibactam but increased susceptibility to piperacillin-tazobactam and imipenem. A total of 81% (12/16) of ceftolozane-tazobactam-resistant isolates with mutations were susceptible to imipenem-relebactam.
ISSN:0066-4804
1098-6596
DOI:10.1128/AAC.00084-21